Mr. Brent Zettl reports

ZYUS LIFE SCIENCES ANNOUNCES COMPLETION OF THE FINAL STUDY VISIT BY THE LAST PATIENT IN PHASE 2A UTOPIA-1 TRIAL EVALUATING NOVEL NON-OPIOID PAIN DRUG

The last patient has completed the final study visit in Zyus Life Sciences Corp.'s phase 2a Utopia-1 (unique treatment of oncology pain in advanced cancer) trial evaluating the efficacy of Trichomylin softgel capsules in patients experiencing moderate to severe cancer-related pain.

Utopia-1 trial is a single-arm, proof-of-concept study designed to investigate the safety and preliminary analgesic efficacy of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. With the completion of the final study visit, the phase 2a Utopia-1 trial has reached the last patient, last visit milestone.

"We are pleased to have completed patient participation in the Utopia-1 trial," said Dr. Julie Stakiw, chief medical officer of Zyus. "Cancer-related pain remains a complex condition to manage, and there remains a need for alternative treatment approaches. We look forward to evaluating the study results and thank the patients and investigators whose participation made this study possible."

"The completion of the last patient visit represents a key milestone for the Utopia-1 trial, and we look forward to analyzing the full data set, including preliminary data observed to date, to inform the continued drug development of Trichomylin softgel capsules," said Brent Zettl, president and chief executive officer of Zyus. "This milestone reflects our ongoing commitment to advancing potential non-opioid treatment options for patients with cancer-related pain."

Top-line results from the phase 2a Utopia-1 trial are expected to be reported in second quarter, following completion of data cleaning and analysis. These findings will build on the encouraging preliminary data previously announced that suggested Trichomylin softgel capsules were effective for pain management, were safe and well tolerated, and indicated potential for opioid sparing.

About Zyus Life Sciences Corp.

Zyus is a life science company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, Zyus aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. Zyus's unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions in pursuit of transformational impact on patients' lives.

We seek Safe Harbor.